The latter half of 2008 was filled first with anticipation and later by debate regarding the impact of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) study [1 ]. The premise for JUPITER originated from an Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/ TexCAPS) substudy, which showed that among patients with lower LDL levels treated with lovastatin, only those with high-sensitivity C reactive protein (hs-CRP) elevation experienced a reduction in coronary events [2]. Inflammation appears to play a critical role in atherogenesis and plaque instability [3], and JUPITER was designed to target patients with inflammation but normal LDL cholesterol levels. In JUPITER, 17 802 patients (men 50 years old and women 60 years old) with an LDL of less than 3.4 mmol (<130 mg/dl) and hs-CRP 2.0 mg/l or more were randomized to treatment with rosuvastatin 20 mg/day or placebo. Over 1.9 years median follow-up, treatment with rosuvastatin resulted in a 44% reduction in major cardiovascular events.
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Despite the dramatic results of JUPITER, the absolute achieved benefit was small due to a low overall cardiovascular event rate (1%/year). The authors also included many so-called 'softer' endpoints as part of the primary endpoint, including arterial revascularization and hospitalization for angina. The number needed to treat (NNT) for 2 years to prevent one major cardiovascular event was 95, while the extrapolated NNT over 5 years was 25. The latter value was smaller than what was seen in the two largest primary prevention trials, AFCAPS/TexCAPS and the West of Scotland Coronary Prevention Study (WOSCOPS) [4, 5] , which suggests that treating patients with an elevated hs-CRP in the absence of LDL cholesterol elevation is at least as efficacious as treating patients with elevated LDL cholesterol. Extrapolating NNT results is problematic, however, particularly in the case of statin therapy where compliance has been shown to significantly diminish over time.
Classification of the JUPITER trial remains uncertain. Should it be considered a primary prevention trial or was it a secondary prevention trial of patients with subclinical atherosclerosis? It has also been debated whether CRP is only a marker of atherosclerosis or if it is truly pathogenic. A recent study of genetic polymorphisms leading to persistently elevated CRP found no association between elevated CRP and ischemic cardiovascular disease, suggesting that hs-CRP is unlikely to be causative [6 ] . Elevated CRP has been associated with metabolic syndrome and appears to provide additional risk stratification in these patients [7] . It is currently unknown whether CRP reflects the severity of metabolic derangements or atherosclerosis, or possibly is an expression of an unidentifiable risk factor that confers additional cardiovascular risk. The patients in JUPITER did have significant risk factors for cardiovascular disease. About 40% of patients had metabolic syndrome, the average BMI was 28, 16% were active smokers and 50% had a Framingham risk score 10% or more, yet subgroup analysis showed similar benefit even in patients without risk factors for cardiovascular disease other than elevated hs-CRP. JUPITER did overcome a major limitation of AFCAPS/ TexCAPS and WOSCOPS, lack of female recruitment. A meta-analysis of primary prevention trials prior to JUPI-TER suggested that statins may not have the same benefit in preventing cardiovascular events in women [8] , and some authors have even speculated that statins could be detrimental when administered to women without established cardiovascular disease. The 6801 women enrolled in JUPITER experienced similar benefits as the 11 001 men, supporting an aggressive prevention strategy regardless of sex.
Most important to clinicians is whether JUPITER is generalizable and immediately applicable. It is interesting that although 52% of the US population has a CRP level more than 2.0 mg/l [9], only 20% of patients screened for JUPI-TER were eventually randomized. Recent estimates are that 33 million older US adults (men 50 years old and women 60 years old) are currently treated with or have an indication for statin use [10] . On the basis of JUPITER, an additional 11 million patients would be eligible for statin therapy. The cost-effectiveness of such a strategy needs to be assessed before widespread implementation. Until this exists, the judicious measurement of hs-CRP may assist clinicians in selecting appropriate candidates for statin therapy who are close to but do not meet current guidelines for treatment.
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